COMPOSITIONS FOR THE TREATMENT OF TUMOUR PATHOLOGIES, COMPRISING INTERNALIN B (IN1B) OF LISTERIA MONOCYTOGENE PROTEIN OR A FRAGMENT THEREOF

摘要

The pathway by which Met is degraded after interacting with In1B, in response to Listeria monocytogenes infection, provides In1B or In1B fragments or peptides, preferably those that interfere with the interaction between In1B and Met, as new cancer treatments that can achieve rapid down-regulation and subsequent degradation of Met. In addition, this pathway highlights methods of screening for other compounds that modulate the interaction between Met and In1B and may also be used therapeutically.